Tuesday, February 7, 2023
wellness India Expo
Home Tags Vaccine

Tag: Vaccine

UW-Madison Global Health Institute partners Ella Foundation to establish first-ever ‘UW-Madison...

Partnership expands the Wisconsin Idea by providing interdisciplinary collaborations with UW-Madison, the Ella Foundation, and Bharat Biotech

Vaccines with efficacy against Omicron variants will gain competitive advantage in...

According to GlobalData’s Pharma Intelligence Center, there are currently 19 COVID-19 vaccines in clinical development in China, with only 3 candidates in Phase III trials

Hester acquires tech from ICAR–NIHSAD to develop a low pathogenic Avian...

The agreement was signed on 27 December 2022 at the office of Agrinnovate India, New Delhi

Corbevax booster in individuals vaccinated with COVAXIN or COVISHEILD gives maximum...

As per AIG study, protein-based vaccine when given as a booster shown to induce not only increased antibody response but also robust T-cell and B-cell (memory cell) response linked with long-term immunity

Takeda’s tetravalent vaccine for Dengue approved for use in European Union

Effective dengue prevention requires a multi-faceted approach, and previous methods have been insufficient for a number of reasons

India will make significant investment in vaccine R&D, assures govt

While efforts are still on to uncover findings about the COVID-19 and the epidemiological models, India is ready to invest in future challenges

Intravacc launches phase I clinical trial of Avacc 10, an intranasal...

Randomized, double blinded, placebo-controlled trial. Evaluation of two doses in 36 volunteers. Mid-term data expected by end Q1 2023

Takeda’s dengue vaccine candidate granted priority review by US-FDA

TAK-003 is being evaluated for the prevention of dengue disease caused by any dengue virus serotype in individuals 4 years through 60 years of age

Indian Immunologicals’ FMD Vaccine becomes world’s first animal vaccine to be...

Drone delivery of vaccines is expected to not only reach remote difficult terrains faster but also help in providing critical vaccines on time

CEPI and SK bioscience partner to advance mRNA vaccine technology

CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus